IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
GLP-1: Acute Effects on Kidney Function in Healthy Men
This study has been completed.
Sponsor:
Jeppe Skov
Collaborator:
Novo Nordisk A/S
Information provided by (Responsible Party):
Jeppe Skov, University of Aarhus
ClinicalTrials.gov Identifier:
NCT01333163
First received: April 8, 2011
Last updated: December 14, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate how Glucagon-Like Peptide 1 (GLP-1) affects kidney function in healthy young men. The hypothesis is that GLP-1 induces a positive effect on kidney hemodynamics.
| Condition | Intervention |
|---|---|
| Kidney Functional | Biological: Human GLP-1 (7-36) amide Biological: Isotone NaCl |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Basic Science |
| Official Title: | GLP-1: Acute Effects on Kidney Function in Healthy Men |
Further study details as provided by Jeppe Skov, University of Aarhus:
Primary Outcome Measures:
- Glomerular Filtration Rate [ Time Frame: Every 20 minutes for 6 hours ]
| Enrollment: | 12 |
| Study Start Date: | May 2011 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: GLP-1 |
Biological: Human GLP-1 (7-36) amide
2 hour IV infusion, 1,5pmol/min/kg.
|
| Placebo Comparator: Placebo |
Biological: Isotone NaCl
2 hours IV infusion.
|
Eligibility| Ages Eligible for Study: | 18 Years to 30 Years (Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy young men
Exclusion Criteria:
- Any chronic diseases
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01333163
Please refer to this study by its ClinicalTrials.gov identifier: NCT01333163
Locations
| Denmark | |
| Klinisk Institut, Afd. MEA, Aarhus Sygehus, NBG | |
| Aarhus C, Denmark, 8000 | |
Sponsors and Collaborators
Jeppe Skov
Novo Nordisk A/S
Investigators
| Principal Investigator: | Jeppe Skov, MD | University of Aarhus |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Jeppe Skov, MD, University of Aarhus |
| ClinicalTrials.gov Identifier: | NCT01333163 History of Changes |
| Other Study ID Numbers: |
VEKRM 29414 |
| Study First Received: | April 8, 2011 |
| Last Updated: | December 14, 2011 |
Additional relevant MeSH terms:
|
Glucagon-Like Peptide 1 Glucagon Incretins Hormones |
Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Gastrointestinal Agents |
ClinicalTrials.gov processed this record on June 28, 2017